Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas

Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Although initially beneficial, TMZ resistance is universal and second-line interventions are an unmet clinical need. Here, we took advantage of...

Full description

Bibliographic Details
Main Authors: Alamillo-Ferrer, C. (Author), Cheng, S.-Y (Author), Drewry, D.H (Author), Erdogdu, B. (Author), Goenka, A. (Author), Goldlust, S.A (Author), Haddad, B.R (Author), Hogg, J.R (Author), Hu, B. (Author), Jin, L. (Author), Pertea, M. (Author), Pickett, J.E (Author), Razaghi, R. (Author), Riggins, R.B (Author), Sadowski, N. (Author), Song, X. (Author), Tiek, D.M (Author), Timp, W. (Author), Wells, C.I (Author), Zuercher, W.J (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items